{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-031713","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.876635+00:00","generated_at":"2026-05-14T22:22:11.758246+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vericel Q1 revenue up 30% to $68.4M, net loss narrows; raises FY revenue guidance to $326-336M","bullets":["Total revenue up 30% to $68.4M; MACI revenue up 22% to $56.4M, Burn Care up 91% to $12.0M.","Net loss narrowed to $6.3M from $11.2M; adjusted EBITDA up 195% to $9.6M (14% of revenue).","Raised full-year 2026 revenue guidance by $10M to $326-336M; reaffirmed ~75% gross margin and ~27% adjusted EBITDA margin.","Free cash flow of $15.1M; cash and investments $211M, no debt.","Received FDA approval for MACI commercial manufacturing at new facility; BARDA award up to $197M for NexoBrid."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-031713","json":"https://secwatch.observer/filing/0001628280-26-031713.json","markdown":"https://secwatch.observer/filing/0001628280-26-031713.md","text":"https://secwatch.observer/filing/0001628280-26-031713.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828026031713/0001628280-26-031713-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828026031713/vcel-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:22:11.758246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}